GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
New Data Add To Confidence
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.
South Korea is ramping up policy and financial support in its continuing efforts to control COVID-19, with new drugs and vaccines set to benefit amid broader infectious disease control measures.